胶质瘤患者的临床试验终点
Clinical trial endpoints for patients with gliomas.
作者信息
Taylor Jennie W, Molinaro Annette M, Butowski Nicholas, Prados Michael
机构信息
Department of Neurological Surgery, University of California San Francisco, San Francisco, California (J.W.T., A.M.M., N.B., M.P.).
Department of Neurology, University of California San Francisco, San Francisco, California (J.W.T.).
出版信息
Neurooncol Pract. 2017 Dec;4(4):201-208. doi: 10.1093/nop/npw034. Epub 2017 Feb 14.
Abstract
Malignant glioma represents a diverse set of molecularly heterogeneous diseases. Few therapeutic agents have been approved despite decades of clinical trials research and pre-clinical investigation. Attempts to refine neuroimaging criteria and recent discovery of the genomic profiles linking tumor subsets to survival outcomes have spurred discussion on a variety of new approaches in clinical trial design and relevant endpoints. Here we focus on those endpoints in clinical trial design for patients with primary glioma and related issues still to be resolved.
摘要
恶性胶质瘤代表了一系列分子异质性疾病。尽管经过了数十年的临床试验研究和临床前研究，但获批的治疗药物寥寥无几。完善神经影像学标准的尝试以及最近发现的将肿瘤亚群与生存结果相关联的基因组图谱，引发了关于临床试验设计中各种新方法及相关终点的讨论。在此，我们聚焦于原发性胶质瘤患者临床试验设计中的那些终点以及仍有待解决的相关问题。
相似文献
1
Clinical trial endpoints for patients with gliomas.胶质瘤患者的临床试验终点
Neurooncol Pract. 2017 Dec;4(4):201-208. doi: 10.1093/nop/npw034. Epub 2017 Feb 14.
2
Pros and cons of current brain tumor imaging.当前脑肿瘤成像的利弊
Neuro Oncol. 2014 Oct;16 Suppl 7(Suppl 7):vii2-11. doi: 10.1093/neuonc/nou224.
3
Endpoints for clinical trials and revised assessment in neuro-oncology.神经肿瘤学临床试验终点和修订评估。
Curr Opin Neurol. 2012 Dec;25(6):780-5. doi: 10.1097/WCO.0b013e328359b45e.
4
Response Assessment in Neuro-Oncology Criteria and Clinical Endpoints.神经肿瘤学标准中的疗效评估与临床终点
Magn Reson Imaging Clin N Am. 2016 Nov;24(4):705-718. doi: 10.1016/j.mric.2016.06.003. Epub 2016 Sep 14.
5
Molecularly targeted therapy for malignant glioma.恶性胶质瘤的分子靶向治疗
Cancer. 2007 Jul 1;110(1):13-24. doi: 10.1002/cncr.22741.
6
Radiotherapy for diffuse brainstem glioma in children and young adults.儿童和青年弥漫性脑干胶质瘤的放射治疗
Cochrane Database Syst Rev. 2016 Jun 27;2016(6):CD010439. doi: 10.1002/14651858.CD010439.pub2.
7
Input of molecular analysis in medical management of primary brain tumor patients.分子分析在原发性脑肿瘤患者医疗管理中的应用。
Rev Neurol (Paris). 2015 Jun-Jul;171(6-7):457-65. doi: 10.1016/j.neurol.2015.04.002. Epub 2015 May 27.
8
A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology.神经肿瘤学治疗失败的转机窗口。
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-8. doi: 10.1200/EDBK_349175.
9
A phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668].柳氮磺胺吡啶治疗进展性恶性胶质瘤安全性和有效性的1-2期前瞻性双盲随机研究：[ISRCTN45828668]研究方案
BMC Cancer. 2006 Jan 31;6:29. doi: 10.1186/1471-2407-6-29.
10
Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.放射治疗肿瘤学组三项恶性胶质瘤试验中预后因素的递归划分分析
J Natl Cancer Inst. 1993 May 5;85(9):704-10. doi: 10.1093/jnci/85.9.704.
引用本文的文献
1
Initiatives Toward Clinical Boron Neutron Capture Therapy in Japan.日本临床硼中子俘获疗法的进展。
Cancer Biother Radiopharm. 2023 Apr;38(3):201-207. doi: 10.1089/cbr.2022.0056. Epub 2022 Nov 14.
2
Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastoma.临床指标、影像组学和基因组学为基于人工智能的胶质母细胞瘤患者总生存期预测提供了协同价值。
Sci Rep. 2022 May 24;12(1):8784. doi: 10.1038/s41598-022-12699-z.
3
Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment.胶质母细胞瘤质子治疗与光子调强放射治疗的II期试验：RANO与临床评估之间无进展生存期的二次分析比较
Neurooncol Adv. 2021 Jun 1;3(1):vdab073. doi: 10.1093/noajnl/vdab073. eCollection 2021 Jan-Dec.
4
Fibroblast Activation Protein Expressing Mesenchymal Cells Promote Glioblastoma Angiogenesis.表达成纤维细胞活化蛋白的间充质细胞促进胶质母细胞瘤血管生成。
Cancers (Basel). 2021 Jul 1;13(13):3304. doi: 10.3390/cancers13133304.
5
Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease.用于治疗中枢神经系统（CNS）转移性疾病的免疫检查点抑制剂
Front Oncol. 2018 Sep 27;8:414. doi: 10.3389/fonc.2018.00414. eCollection 2018.
本文引用的文献
1
The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria.神经肿瘤学中的神经功能评估（NANO）量表：一种用于评估神经功能以纳入神经肿瘤学疗效评估（RANO）标准的工具。
Neuro Oncol. 2017 May 1;19(5):625-635. doi: 10.1093/neuonc/nox029.
2
A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.一项针对复发性胶质母细胞瘤成年患者的随机II期试验，比较标准剂量贝伐单抗与低剂量贝伐单抗加洛莫司汀（CCNU）的疗效。
J Neurooncol. 2016 Sep;129(3):487-494. doi: 10.1007/s11060-016-2195-9. Epub 2016 Jul 12.
3
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.基于肿瘤中1p/19q、异柠檬酸脱氢酶（IDH）和端粒酶逆转录酶（TERT）启动子突变的胶质瘤分组
N Engl J Med. 2015 Jun 25;372(26):2499-508. doi: 10.1056/NEJMoa1407279. Epub 2015 Jun 10.
4
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.在新诊断的胶质母细胞瘤中贝伐单抗、替莫唑胺和放疗的随机 III 期研究中的健康相关生活质量。
J Clin Oncol. 2015 Jul 1;33(19):2166-75. doi: 10.1200/JCO.2014.60.3217. Epub 2015 May 26.
5
Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.抗血管生成和免疫/靶向治疗时代胶质母细胞瘤的神经影像学陷阱 - 检测虚幻的疾病，定义反应。
Front Neurol. 2015 Feb 23;6:33. doi: 10.3389/fneur.2015.00033. eCollection 2015.
6
Patient reported endpoints for measuring clinical benefit in (high grade glioma) primary brain tumor patients.患者报告的用于衡量（高级别胶质瘤）原发性脑肿瘤患者临床获益的终点指标。
Curr Treat Options Oncol. 2014 Dec;15(4):519-28. doi: 10.1007/s11864-014-0302-8.
7
Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.贝伐珠单抗单药或洛莫司汀单药与贝伐珠单抗联合洛莫司汀治疗复发性胶质母细胞瘤患者的比较（BELOB 试验）：一项随机对照 2 期试验。
Lancet Oncol. 2014 Aug;15(9):943-53. doi: 10.1016/S1470-2045(14)70314-6. Epub 2014 Jul 15.
8
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.贝伐珠单抗联合放疗-替莫唑胺治疗新诊断的胶质母细胞瘤。
N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345.
9
A randomized trial of bevacizumab for newly diagnosed glioblastoma.贝伐珠单抗治疗新诊断的胶质母细胞瘤的随机试验。
N Engl J Med. 2014 Feb 20;370(8):699-708. doi: 10.1056/NEJMoa1308573.
10
Biomarker-based adaptive trials for patients with glioblastoma--lessons from I-SPY 2.基于生物标志物的胶质母细胞瘤患者适应性试验——来自 I-SPY 2 的经验教训。
Neuro Oncol. 2013 Aug;15(8):972-8. doi: 10.1093/neuonc/not088. Epub 2013 Jul 14.
Zotero 插件